Skip to main content
Fig. 2 | Human Genomics

Fig. 2

From: Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response

Fig. 2

Heatmap depicting DMRs upon comparing individuals with MDS who progressed to AML against those who did not (A). Areas hypomethylated are depicted with blue and areas hypermethylated are depicted with red. Network map (B) depicting interactions between DMRs with fold change values above 3.5 and other proteins involved in molecular pathways. These DMRs are also found within the heatmap (A). Progress to aggressive AML: S3, S14, S16, S7, S9, S20, S2, S8, S18, S17, S21; Without progress to aggressive AML: S22, S19, S6, S13, S15, S11, S12

Back to article page

Human Genomics

ISSN: 1479-7364